Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial - Summary - MDSpire
Advertisement
Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial
To investigate the efficacy and safety of benvitimod compared to halometasone in treating moderate-to-severe chronic hand eczema (CHE), highlighting the need for alternative treatments.
Key Findings:
Benvitimod demonstrated similar efficacy to halometasone in treating moderate-to-severe CHE.
Benvitimod exhibited a more favorable safety profile and tolerability compared to halometasone.
Interpretation:
Benvitimod may serve as an effective alternative to traditional corticosteroid treatments for patients with moderate-to-severe CHE, particularly for those who are refractory to or refuse long-term corticosteroid use.
Limitations:
Single-center study may limit generalizability.
Short follow-up period may not capture long-term efficacy and safety.
Conclusion:
Benvitimod is a promising nonsteroidal treatment option for moderate-to-severe CHE, offering comparable efficacy to halometasone with improved safety.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
